





Miraculins Announces Grant of Options

WINNIPEG, Manitoba – July 26, 2011 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment tools for unmet clinical needs, announces today that it has granted an aggregate of 300,000 stock options at an exercise price of \$0.10 per common share, to the three directors who were newly appointed to the Board at the Company's most recent shareholders meeting. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.

For more information, please contact:

Christopher J. Moreau President and CEO Miraculins Inc. Ph: 204-477-7599 Fax: 204-453-1546

info@miraculins.com www.miraculins.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.